Search

Displaying results 931 - 940 of 7674 in total
  1. Drug

    Mecasermin rinfabate

    go.drugbank.com/drugs/DB14751
    ApprovedInvestigational

    Mecasermin rinfabate manufactured by Insmed Incorporated under the brand name Iplex was approved by the FDA in 2005[L5722].

  2. Drug

    Gepirone

    go.drugbank.com/drugs/DB12184
    Approved

    [A261670,A261675,A182315] Gepirone was approved by the FDA on September 28, 2023, under the brand name EXXUA for the treatment of adults with major depressive disorder. … Although earlier clinical trials showed promising results for gepirone, its formulation as an immediate-release tablet necessitates frequent administration due to the short half-lives.

  3. Drug

    Omacetaxine mepesuccinate

    go.drugbank.com/drugs/DB04865
    ApprovedInvestigationalWithdrawn

    Most recently, in October 2012, omacetaxine mepesuccinate was marketed under the brand name Synribo and FDA approved for patients who are intolerant and/or resistant to two or more tyrosine kinase inhibitors … Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the plant, Cephalotaxus species.

    Synonyms: mepesuccinato de omacetaxina
  4. Drug

    Regdanvimab

    go.drugbank.com/drugs/DB16405
    ApprovedWithdrawn

    [A235830,A241995] It received its first full approval in South Korea in September 2021,[A241995] followed by the EU in November 2021.[L39130]

  5. Drug

    Enzacamene

    go.drugbank.com/drugs/DB11219
    Approved

    Commonly known as 4-methylbenzylidene-camphor (4-MBC), enzacamene is a camphor derivative and an organic chemical UV-B filter. … While its effects on the human reproductive system as an endocrine disruptor are being investigated, its use in over-the-counter and cosmetic products is approved by Health Canada.

    Mixtures: Bain De Soleil Protection Lotion SPF 15Synonyms: Enzacamene D-L form, 3-(p-Methylbenzylidene)-DL-camphor
  6. Drug

    Finerenone

    go.drugbank.com/drugs/DB16165
    ApprovedInvestigational

    [A236544] So far, finerenone is the only nonsteroidal mineralocorticoid receptor antagonist to be FDA approved. … mineralocorticoid receptor antagonist indicated to reduce the risk of sustained decline in glomerular filtration rate, end stage kidney disease, cardiovascular death, heart attacks, and hospitalization due

  7. Drug

    Crofelemer

    go.drugbank.com/drugs/DB04941
    ApprovedInvestigational

    It is marketed under the brand name Fulyzaq and indicated for the symptomatic treatment of non-infectious diarrhea in adult patients with HIV/AIDS who are taking antiretroviral therapy.

  8. Drug

    Tralokinumab

    go.drugbank.com/drugs/DB12169
    ApprovedInvestigational

    Tralokinumab was first approved for the treatment of atopic dermatitis by the EMA in June 2021, under the brand name Adtralza (Leo Pharma), and was subsequently approved in Canada in October 2021 and the … Atopic dermatitis (AD) is an inflammatory skin disorder that causes skin inflammation, skin barrier dysfunction, and chronic pruritus.

  9. Drug

    Gadodiamide

    go.drugbank.com/drugs/DB00225
    ApprovedInvestigational

    [A263096] Approved by the FDA in 1993, gadodiamide is the first non-ionic GBCA to be used. … [A263101] However, since linear, non-ionic GBCA is less stable than macrocyclic or ionic GBCA, gadodiamide can potentially lead to more gadolinium retention in the brain and thus more likely to cause side

  10. Drug

    Lofexidine

    go.drugbank.com/drugs/DB04948
    ApprovedInvestigational

    [T209] Lofexidine was developed by US Woldmeds LLC and it was approved by the FDA on May 16, 2018.[L2794] … [A33084] It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hypertension than clonidine.